| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Twist Bioscience (NASDAQ:TWST) will release its quarterly earnings report on Friday, 2025-11-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Twist Bioscience to report an earnings per share (EPS) of $-0.46.
Anticipation surrounds Twist Bioscience's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
In the previous earnings release, the company beat EPS by $0.09, leading to a 8.9% drop in the share price the following trading session.
Here's a look at Twist Bioscience's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.56 | -0.56 | -0.63 | -0.69 |
| EPS Actual | -0.47 | -0.66 | -0.53 | -0.59 |
| Price Change % | -9.00 | -9.00 | -1.00 | 0.00 |
Shares of Twist Bioscience were trading at $31.87 as of November 12. Over the last 52-week period, shares are down 13.61%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Twist Bioscience.
Analysts have given Twist Bioscience a total of 3 ratings, with the consensus rating being Outperform. The average one-year price target is $41.0, indicating a potential 28.65% upside.
The analysis below examines the analyst ratings and average 1-year price targets of Sarepta Therapeutics, uniQure and Vericel, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
The peer analysis summary outlines pivotal metrics for Sarepta Therapeutics, uniQure and Vericel, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Twist Bioscience | Outperform | 17.91% | $51.30M | 4.44% |
| Sarepta Therapeutics | Neutral | -14.52% | $248.58M | -13.44% |
| uniQure | Buy | 61.83% | $3.30M | -71.66% |
| Vericel | Buy | 16.58% | $49.59M | 1.61% |
Key Takeaway:
Twist Bioscience ranks first in revenue growth among its peers. It ranks second in gross profit and return on equity.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Twist Bioscience's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.91% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Twist Bioscience's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Twist Bioscience's ROE stands out, surpassing industry averages. With an impressive ROE of 4.44%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Twist Bioscience's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.29%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Twist Bioscience adopts a prudent financial strategy, indicating a balanced approach to debt management.
To track all earnings releases for Twist Bioscience visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TWST
